Antibody Production

Gram-scale Antibody Production in Your Cell Line of Choice


Transiently express milli- to multi-gram quantities of antibodies from a single 30-minute transfection in your biomanufacturing host to rapidly identify and characterize top candidates and delay the time and investment of stable cell line generation.

  • Express antibodies, bispecifics, Fc fusions and fragments
  • Initiate antibody development in your biomanufacturing cell background
  • No special reagents, cells or media required
  • High efficiency, high viability transfection of CHO cell lines
  • Produce high-quality antibodies within days
  • Seamless scalability supports R&D through cGMP pilots and toxicology studies
  • Use Your CHO Cell Line of Choice



Antibody Titers >500 mg/L Within 6 Days & >2 g/L in Less Than 2 Weeks



CHO-S cells were transfected with an IgG expression plasmid via small-scale electroporation. Cells were plated at approximately 4×106 cells/mL post electroporation.  Titer was verified by both ELISA and Protein A capture assays.

High Titer Antibody Production in CHO-K1SV Cells



High Titer Antibody Production in CHO-K1SV Cells. CHO-K1SV cells were transfected via small-scale electroporation or PEI with an IgG expression plasmid and cultured for 13 days or 5 days, respectively. Viability of PEI transfected cells did not allow culturing past day 5. Titers were measured on days 5, 9, and 13 post electroporation. Titers were measured in the PEI transfected cells on day 5. The day 5 titer data indicated clear superiority of MaxCyte electroporation vs. PEI, and the titer data on day 13 revealed productivity exceeding 1 g/L in STX-transfected CHO-K1SV cells.

Express High-Quality, Functional Bispecifics


CHO-S cells were co-transfected with plasmids encoding a Her2 x CD16 tribody and proteins were enriched from conditioned media samples. Proteins were assayed by capillary electrophoresis under reducing and non-reducing conditions. Arrows indicate bands of the expected sizes for single chains and intact tribody. B). SKBR-3 cells (derived from human breast cancer) were incubated with [(Her2)2 x CD16] tribody or with CD19 x CD3 BiTE molecules (negative control). FACS analysis showed binding of the tribody to Her2 antigens on SKBR-3 cells, whereas binding was not observed using the negative control CD19 x CD3 bispecific molecules. Data Courtesy of Dr. Matthias Peipp, Division of Stem Cell Transplantation and Immunotherapy, Christian-Albrechts-University

Produce High Quality Protein


CHO-S cells were electroporated with a bicistronic expression plasmid encoding the components of a bispecific diabody. Total secreted diabody concentrations were measured using ELISA on various days post transfection. Diabody titers were more than twenty-fold higher using MaxCyte electroporation compared to customer’s previous lipid transfection method. Analysis of purified proteins showed that most all of the MaxCyte produced protein was in a monomeric form.

Superior Production Through Superior Cell-Engineering



MaxCyte routinely outperforms other transfection methods for production of a variety of protein types in our customers’ hands. Titers for 16 different proteins were higher following MaxCyte electroporation compared to lipid and polymer transfections. All side-by-side comparisons were performed in customer laboratories.

Unmatched, Seamless Scalability


Two sets of 2×1010 CHO-S cells were transfected using large-scale electroporation (EP) with an hIgG expression plasmid on the MaxCyte STX and VLX instruments. Following EP, cells were seeded into 1-L shake flasks. An independent transfection was performed on the VLX with 2×1011 cells, and cells seeded into a 15-L WAVE bag at the same density as cells in shake flasks. Relative titers for all three sets of cells measured two weeks post EP demonstrate reproducibility and scalability of Flow Electroporation™ Technology.

Resource Center

Put the MaxCyte Platform to Work For You

Read More

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo